CAMBRIDGE, Mass., February 07, 2025--eGenesis announces second patient successfully transplanted with genetically engineered ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

Decreased Mobility It's common to see cats lounging around the house, but a noticeable decline in mobility can indicate ...